RemeGen grabs one of the world's largest ever biotech IPOs

RemeGen has raised $515 million on the Hong Kong exchange in one of the largest biotech IPOs ever produced.

The largest to date in 2020, and one of the biggest after Moderna’s $600 million-plus IPO a few years back, the Yantai-based biotech in China will use its major cash haul toward its healthy pipeline of mid- to late-stage efforts.

This includes telitacicept and disitamab vedotin, both slated for approval within the next three to eight months.